{"id":"NCT02368314","sponsor":"Biocad","briefTitle":"A Safety and Efficacy Study of BCD-080 Compared to Clexan for Deep Vein Thrombosis Prophylaxis at Orthopedic Surgeries","officialTitle":"International Multicenter Randomized Double-blind Comparative Clinical Trial of Safety and Efficacy of BCD-080 (JSC BIOCAD, Russia) and ClexanÂ® (Sanofi Aventis France, France) for Deep Vein Thrombosis Prophylaxis at Orthopedic Surgeries","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01","primaryCompletion":"2015-12","completion":"2015-12","firstPosted":"2015-02-23","resultsPosted":"2016-10-24","lastUpdate":"2016-10-24"},"enrollment":124,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Deep Vein Thrombosis"],"interventions":[{"type":"DRUG","name":"Sodium Enoxaparine","otherNames":["Clexane (Sodium Enoxaparine)","BCD-080 (Sodium Enoxaparine)"]}],"arms":[{"label":"BCD-080","type":"EXPERIMENTAL"},{"label":"Clexane","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to prove equivalence of efficacy and safety of BCD-080 and Clexan for deep vein thrombosis and embolism prophylaxis at orthopedic surgeries.","primaryOutcome":{"measure":"Frequency of DVT.","timeFrame":"During the treatment period (14 days)","effectByArm":[{"arm":"BCD-080","deltaMin":0,"sd":null},{"arm":"Clexane","deltaMin":2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.226"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":64},"commonTop":["Anemia","Elevated D-dimer","Arterial hypertension","Hyperglycemia","Elevated gamma glutamyl tranferase"]}}